British drugmaker GSK said on Tuesday its experimental therapy, linerixibat, met its main goal in a late-stage trial to treat ...
Significant correlation shown between blood levels and symptom relief; TH104 was well tolerated with no unexpected ...
Ipsen presents 3 late-breaking presentations and 8 abstracts across rare cholestatic liver disease portfolio at AASLD 2024 ...
GSK has reported promising results with a drug to treat the severe itching that plagues patients with rare cholestatic liver ...
Tharimmune (THAR) presented new TH104 clinical data at the American Association for the Study of Liver Disease The Liver Meeting 2024, underway in San Diego from November 15-19. The Phase 1 trial was ...
Ipsen presents three late-breaking presentations and eight abstracts across rare cholestatic liver disease portfolio at AASLD 2024Elafibranor was granted marketing authorisation for the treatment of ...
Ipsen presents 3 late-breaking presentations and 8 abstracts across rare cholestatic liver disease portfolio at AASLD 2024Iqirvo approved for use ...
Journalist Annie Lowrey has a rare disease that causes a near-constant itch that doesn't respond to most treatments. She ...
Primary biliary cholangitis (PBC) has typically been considered a rare condition, with a pooled global estimated incidence of ...
Peking University-led researchers have modified an existing treatment for liver disease that does not cause itchiness, a common side effect of existing treatments. Chronic itch is a debilitating ...